Brief: Rhythm Pharmaceuticals Announces FDA Acceptance Of sNDA For Setmelanotide In Acquired Hypothalamic Obesity
20/08/2025 21:04
Aug 20 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY RHYTHM PHARMACEUTICALS INC - FDA GRANTS PRIORITY REVIEW WITH PDUFA DATE DECEMBER 20, 2025 RHYTHM PHARMACEUTICALS INC - STUDY MET PRIMARY ENDPOINT WITH -19.8% PLACEBO-ADJUSTED BMI REDUCTION Source text: ID:nGNX5kkZ9f Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand